Investor Presentaiton

Financial Snapshot Quarter ended 30-Jun-23 31-Mar-23 30-Jun-22 Revenue from operations Other Income 3,440.26 3,643.90 3,387.99 Year ended 31-Mar-23 13,300.80 100.59 107.55 108.98 445.52 Total Income 3,540.85 3,751.45 3,496.97 13,746.32 EBITDA 1,799.41 1,853.83 1,656.37 6,276.30 EBITDA Margin 50.82% 49.42% 47.37% 45.66% EBIT 1,687.93 1,747.55 1,550.89 5,847.85 EBIT Margin 47.67% 46.58% 44.35% 42.54% Finance costs 11.47 22.90 14.33 Depreciation 111.48 106.27 105.48 53.92 428.45 Taxes 433.53 423.04 396.05 1,467.91 Taxes to PBT 25.86% 24.53% 25.78% 25.34% PAT (Standalone) 1,242.94 1,301.62 1,140.52 4,326.03 PAT Margin (Standalone) 35.10% 34.70% 32.61% 31.47% Associate Company PAT (Consolidated) 1,205.90 1,239.71 1,075.42 4,112.90 PAT Margin (Consolidated) 34.06% 33.05% 30.75% 29.92% EPS (Standalore) 4.88 5.11 4.48 16.99 EPS (Consolidated) 4.74 4.87 4.22 16.16 Paid up share capital (Re.1/sh) 254.56 254.56 254.56 254.56 All figures are in INR Million, other than ratios and EPS SUVEN 10 PHARMA

View entire presentation